Zevra Therapeutics Sells $150 Million FDA Priority Review Voucher

In a significant development in the pharmaceutical industry, Zevra Therapeutics has announced the sale of a priority review voucher to an undisclosed buyer for $150 million. The voucher was initially awarded to Zevra following the FDA approval of Miplyffa, their pioneering treatment for Niemann Pick disease type C, a rare metabolic disorder.

Despite having other drug candidates in its pipeline that could potentially benefit from expedited FDA review, Zevra has opted to sell the voucher. This strategic move highlights the high value and demand for such vouchers in the biotech sector, which allow for faster regulatory review of new drugs and can be critical in bringing treatments to market more swiftly.

The transaction details remain confidential as both parties have not disclosed further information regarding the sale. This sale marks a notable moment for Zevra Therapeutics as it continues to make strides in treating rare diseases with innovative therapies.

Date: 28 February, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Anne Wojcicki’s Bold Move to Reclaim 23andMe Sparks Debate in Biotech Industry Character Biosciences Secures $93M for Clinical Trials Targeting Dry AMD FDA Approves New Oral Antibiotic for Urinary Tract Infections Pharmaceutical Firms Face Hurdles: Global Drug Patent Protection Requires In-Depth Market Analysis and Timely Filings.

Author

Mark Chiang